Young smiling boy
gray picture on left of breadcrumbs
 > Home  > Medical  > conclusions  > qr

References: Q, R

  • Quintana, H., and M. Keshavan. 1995. Case study: Risperidone in children and adolescents with schizophrenia. J. Am. Acad. Child. Adolesc. Psychiatry 34:1292-1296.
  • Racusin, R., K. Kovner-Kline, and B. H. King. 1999. Selective serotonin reuptake inhibitors in intellectual disability. Ment. Retard. Dev. Disabil. Res. Rev. 5:264-269.
  • Rapoport, J. L. 1988. The neurobiology of obsessive-compulsive disorder. JAMA 260:2888-2890.
  • Rapoport, J. L., D. O. Quinn, G. Bradbard, K. D. Riddle, and S. E. Brook. 1974. Imipramine and methylphenidate treatment of hyperactive boys. Arch. Gen. Psychiatry 30:789-793.
  • Rappley, M. D., P. B. Mullan, F. J. Alvarez, I. U. Eneli, J. Wang, and J. C. Gardiner. 1999. Diagnosis of attention-deficit/hyperactivity disorder and use of psychotropic medication in very young children [see comments]. Arch. Pediatr. Adolesc. Med. 153:1039-1045.
  • Raskin, L. A., S. E. Shaywitz, B. A. Shaywitz, G. M. Anderson, and D. J. Cohen. 1984. Neurochemical correlates of attention deficit disorder. Pediatr. Clin. North Am. 31:387-396.
  • Ratey, J. J., K. Sovner, E. Mikkelsen, and H. E. Chmielinski. 1989. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J. Clin. Psychiatry 50:382-384.
  • Reid, A. H., G. T. Naylor, and D. S. G. Kay. 1981. A double-blind placebo-controlled crossover trial of carbamazepine in overactive, severely mentally handicapped patients. Psychol. Med. 11:109-113.
  • Reiss, A. L., M. T. Abrams, R. Greenlaw, L. Freund, and M. B. Denckla. 1995. Neurodevelopmental effects of the FMR-1 full mutation in humans. Nat. Med. 1:159-167.
  • Reynolds, E. H. 1967. Effects of folic acid on the mental state and fit frequency of drug treated epileptic patients. Lancet 1:1086-1088.
  • Rey-Sanchez, F., and J. R. Gutierrez-Casares. 1997. Paroxetine in children with major depressive disorder: An open trial. J. Am. Acad. Child Adolesc. Psychiatry 36:1443-1447.
  • Riddle, M. A., B. Geller, and N. Ryan. 1993. Another sudden death in a child treated with desipramine. J. Am. Acad. Child Adolesc. Psychiatry 32:792-796.
  • Riley, K., L. O. Ikle, and R. J. Hagerman. 2000. A randomized, double-blind comparative trial of Adderall in the treatment of attention deficit disorder in children with fragile X. Presented at the Seventh International Fragile X Conference, Los Angeles, July 19-23.
  • Ritvo, E. R., R. Ritvo, A. Yuwiler, and A. Brothers. 1993. Elevated daytime melatonin concentrations in autism: A pilot study. Eur. Child Adolesc. Psychiatry 2:75-78.
  • Rogers, S. J., 2000. Interventions that facilitate socialization in children with autism. J. Autism Dev. Disord. 5:399-409.
  • Rogers, S. J., and H. Lewis. 1989. An effective day treatment model for young children with pervasive developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry 28:207-214.
  • Rosenberg, D. R., J. Holttum, and S. Gershon. 1994. Textbook of pharmacotherapy for child and adolescent psychiatric disorders. New York: Brunner/Mazel Publishers.
  • Rosenberg, D. R., C. M. Stewart, K. D. Fitzgerald, V. Tawile, and E. Carroll. 1999. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry 38:1180-1185.
  • Rosenberg, D. R., F. P. MacMaster, M. S. Keshavan, K. D. Fitzgerald, C. M. Stewart, and G. J. Moore. 2000. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J. Am. Acad. Child Adolesc. Psychiatry 39:1096-1103.
  • Rosenblatt, D. S., E. A. Duschenes, F. V. Hellstrom, M. S. Golick, M. J. Vekemans, S. F. Zeesman, and E. Andermann. 1985. Folic acid blinded trial in identical twins with fragile X syndrome. Am. J. Hum. Genet. 37:543-552.
  • Rosh, J. R., S. F. Dellert, M. Narkewicz, A. Birnbaum, and G. Whitington. 1998. Four cases of severe hepatotoxicity associated with pemoline: Possible autoimmune pathogenesis. Pediatrics 101:921-923.
  • Rosler, A., and E. Witztum. 1998. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone [see comments]. N. Engl. J. Med. 338:416-422.
  • Ruedrich, S., T. P. Swales, C. Fossaceca, J. Toliver, and A. Rutkowski. 1999. Effect of divalproex sodium on aggression and self-injurious behaviour in adults with intellectual disability: A retrospective review. J. Intellect. Disabil. Res. 43:105-111.
  • Ryan, N. D., V. S. Bhatara, and J. M. Perel. 1999. Mood stabilizers in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry 38:529-536.
     

This article is not intended to give medical advice for individual cases.  Any change in medical treatment should be done in consultation with appropriate medical personnel. This article is written for medical professionals.  Some of the terms will be unfamiliar to those who are not trained in medical fields.

*This article is from the chapter on treatment in the 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research edited by Randi Jenssen Hagerman, M.D. and Paul Hagerman, M.D., Ph.D., to be published May 2002.  It is included with permission from The Johns Hopkins University Press. References to other chapters refer to chapters in the book which are not included as part of this website.

The complete 3rd edition of Fragile X Syndrome: Diagnosis, Treatment, and Research can be ordered from the National Fragile X Foundation by calling 1-800-688-8765 or from The Johns Hopkins University Press at 1-800-537-5487.

Medical Follow-up   Pharmacotherapy   Future Prospects
Outline   Medications   Medical Conditions
References: A, B, C, D, EF, G, H, IJ, K, L, M, NOP, QR, S, T, UVWXYZ
 
back to homehow to navigatesite map creditsprivacycontact usdisclaimer

© copyright 1998-2008 NFXF
 
Medication can be important in the treatment of fragile X related behavior problems
TELL A FRIEND